How have ARCT and DMAC total returns compared?

Over the past 10 years, ARCT delivered -2.54% and DMAC delivered 7.89% annualized total return. Past performance doesn't predict future results.

Arcturus Therapeutics Holdings Inc. (ARCT) vs DiaMedica Therapeutics Inc. (DMAC)

A side-by-side comparison of Arcturus Therapeutics Holdings Inc. and DiaMedica Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARCT

Arcturus Therapeutics Holdings Inc.

$379M

$13.33HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT

DMAC

DiaMedica Therapeutics Inc.

$449M

$8.33HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT

Total return — ARCT vs DMAC

growth of $100 · dividends reinvested · last 10y

ARCT -18.2% (-2.0%/yr)DMAC +113.7% (+7.9%/yr)DMAC compounded faster over this window

ARCT DMAC

ARCT vs DMAC: by the numbers

•DMAC is the larger company ($449M vs $379M market cap).
•Both run net losses; DMAC's is the smaller (0.00% vs -391.90% net margin).

Metrics side by side

Valuation

Metric	ARCT	DMAC
P/S ratio	15.92	N/A
P/B ratio	2.21	11.71

Profitability

Metric	ARCT	DMAC
Gross margin	95.50%	0.00%
Operating margin	-111.51%	0.00%
Net margin	-391.90%	0.00%
ROE	-54.29%	-97.92%
ROIC	-54.07%	-100.87%

Growth (annualized)

Metric	ARCT	DMAC
Revenue CAGR (5Y)	22.30%	N/A
Total return CAGR (5Y)	-18.73%	16.41%

Frequently asked

How have ARCT and DMAC total returns compared?: Over the past 10 years, ARCT delivered -2.54% and DMAC delivered 7.89% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARCT analysis Full DMAC analysis Interactive comparison tool

Dig into the metrics

Arcturus Therapeutics ROE DiaMedica Therapeutics ROE Arcturus Therapeutics operating margin DiaMedica Therapeutics operating margin Arcturus Therapeutics revenue growth DiaMedica Therapeutics revenue growth Arcturus Therapeutics free cash flow DiaMedica Therapeutics free cash flow

Arcturus Therapeutics & DiaMedica Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.